Oral HMO Compositions for Non-Infant Executive Function Support
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a safe and effective means to prevent or manage executive function issues or disorders in non-infant humans, as existing treatments are often inadequate or have significant side effects, and there are limited preventive approaches for at-risk individuals.
Innovation Solution
The use of human milk oligosaccharides (HMOs) or synthetic compositions containing HMOs, including bifidobacteria, to enhance executive function, prevent sub-optimal functioning, and improve myelination in the pre-frontal cortex region of the brain through oral or enteral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for executive function issues are used, then some therapeutic effect may be achieved, but significant side effects occur and patient compliance reduces
Solution Approach 1:
The patent employs human milk oligosaccharides (HMOs) as a natural, biodegradable prebiotic substance that serves as a safe alternative to conventional pharmaceutical treatments. HMOs are administered orally and work through physiological mechanisms to improve executive function without the harmful side effects of medications such as stimulants, antidepressants, or antipsychotics. The substance is metabolized and eliminated naturally, providing a disposable-safe treatment approach.
Solution Approach 2:
The patent changes the fundamental parameter of treatment approach from pharmacological intervention to nutritional supplementation. By administering HMOs at specific dosages (e.g., 1-20 grams per day for adults, 0.1-5 grams per day for children), the treatment modifies the biochemical environment in the gut and brain to promote executive function improvement without introducing harmful chemical compounds associated with traditional medications.
2Reliability
If conventional treatments are administered, then some executive function improvement may occur, but patient compliance decreases due to serious side effects
Solution Approach 1:
The patent replaces compliance-reducing medications with a safe, naturally-derived prebiotic substance that patients are more willing to take long-term. HMOs can be administered in various forms including capsules, tablets, or incorporated into food products, making the treatment easy to integrate into daily routines without the burden of managing serious side effects.
Solution Approach 2:
The treatment leverages the body's own physiological systems by utilizing the gut-brain axis. HMOs are metabolized by gut microbiota to produce short-chain fatty acids and other bioactive compounds that naturally cross the blood-brain barrier and support executive function. This self-service mechanism eliminates the need for complex medication regimens and reduces compliance barriers.
3Reliability
If existing therapeutic approaches are used, then treatment of diagnosed disorders may occur, but preventive approaches for at-risk individuals are extremely limited
Solution Approach 1:
The patent enables preventive intervention by administering HMOs to at-risk populations before executive function disorders fully develop. This includes individuals with early signs of cognitive decline, those with family history of neurodegenerative diseases, or individuals experiencing temporary executive function issues due to stress, fatigue, or lifestyle factors. The prebiotic mechanism can be activated early to prevent or delay disorder onset.
Solution Approach 2:
The patent creates a versatile treatment that serves multiple functions: it treats diagnosed executive function disorders, prevents disorders in at-risk individuals, and supports general cognitive health in the population. HMOs can be administered across different age groups and clinical presentations, making the approach universally applicable rather than limited to specific diagnostic categories.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
HMOs effectively enhance executive function, prevent sub-optimal functioning, and improve myelination, offering a safe and well-tolerated solution for non-infants, particularly those at risk or with diagnosed disorders such as ADHD and Alzheimer's disease.
Implementation Method 1
Human milk oligosaccharides (HMOs) have recently been identified as key components of human milk that are not digested by the infant gut, but rather are fermented by the infant gut microbiota to produce short chain fatty acids (SCFAs) and other metabolites with immune-modulating and brain-developmental properties.
Data Source
AI summary
Use of a human milk oligosaccharide (HMO), or a nutritional composition comprising a human milk oligosaccharide, to enhance executive function in a non-infant, to prevent and/or reduce the risk of sub-optimal executive function in a non-infant, to manage sub-optimal executive functioning in a non-infant, and/or to improve myelination to mature the pre-frontal cortex region of the brain in a non-infant, as well as synthetic compositions of HMOs and packs comprising at least 14 individual daily doses of an effective amount of at least one HMO for such a use.